Cimicoxib for the Treatment of Major Depression (SECIM)
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective
COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo
in patients with major depression. This clinical study is based on the assumption that
adjunctive treatment of major depression with a COX-2 inhibitor may be beneficial.